

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Section 1: Identification

Product name : Cyclosporine Formulation

Other means of identification : Optimmune (A007869)
OPTIMMUNE OPHTHALMIC OINTMENT (51551)

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Carcinogenicity : Category 1

Reproductive toxicity : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H350 May cause cancer.
H360Df May damage the unborn child. Suspected of damaging
fertility.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	≥ 50 -< 70
Cyclosporine	59865-13-3	≥ 0.1 -< 1

Section 4: First-aid measures

- | | |
|---|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : May cause cancer.
May damage the unborn child. Suspected of damaging fertility. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Section 5: Fire-fighting measures

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe vapours or spray mist.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	WES-TWA (Mist)	5 mg/m ³	NZ OEL
		WES-STEL (Mist)	10 mg/m ³	NZ OEL
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
Cyclosporine	59865-13-3	TWA	10 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	ointment
Colour	:	colourless, to, light yellow
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics	:	
Particle size	:	Not applicable

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Petrolatum:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Cyclosporine:

Acute oral toxicity : LD50 (Rat): 1,480 mg/kg
LD50 (Mouse): 2,329 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): 107 mg/kg
Application Route: Intravenous
LD50 (Rat): 25.8 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:**Petrolatum:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Cyclosporine:

Remarks : No data available

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Petrolatum:**

Species	:	Rabbit
Result	:	No eye irritation
Method	:	OECD Test Guideline 405
Remarks	:	Based on data from similar materials

Cyclosporine:

Remarks	:	No data available May irritate eyes.
---------	---	---

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Petrolatum:**

Test Type	:	Buehler Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

Cyclosporine:

Remarks	:	May cause sensitisation of susceptible persons.
---------	---	---

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Petrolatum:**

Genotoxicity in vitro	:	Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials
-----------------------	---	---

Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
----------------------	---	--

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Cyclosporine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster cells
Result: negative

Test Type: sister chromatid exchange assay
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Chinese hamster
Cell type: Bone marrow
Result: negative

Test Type: Chromosomal aberration
Species: Mouse
Result: negative

Carcinogenicity

May cause cancer.

Components:**Petrolatum:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Cyclosporine:

Species : Mouse
Application Route : Oral
Exposure time : 78 weeks
LOAEL : 4 mg/kg body weight
Result : positive
Target Organs : Liver, lymphatic system

Species : Rat

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Application Route : Oral
Exposure time : 2 Years
LOAEL : 0.5 mg/kg body weight
Result : positive
Target Organs : Pancreas

Species : Humans
Result : May cause cancer.
Target Organs : Immune system, Skin
Remarks : Information taken from reference works and the literature.

Carcinogenicity - Assessment : May cause cancer.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Petrolatum:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Skin contact
Result: negative
Remarks: Based on data from similar materials

Cyclosporine:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity F1: LOAEL: 15 mg/kg body weight
Result: No effects on fertility, Effect on reproduction capacity

Test Type: Fertility
Species: Rat, males
Application Route: Subcutaneous
Fertility: LOAEL: 10 mg/kg body weight
Result: Reduced fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Re-

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

duced foetal weight, foetal mortality, Retardations, Teratogenic effects

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 100 mg/kg body weight

Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced foetal weight, foetal mortality, Retardations, Teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Target Organs: Kidney

Result: Visceral malformations

Test Type: Development

Species: Rat

Application Route: Intravenous

Developmental Toxicity: LOAEL: 12 mg/kg body weight

Target Organs: Heart

Result: Visceral malformations

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**Cyclosporine:**

Target Organs : Kidney, Liver, Immune system

Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Petrolatum:**

Species : Rat

NOAEL : 5,000 mg/kg

Application Route : Ingestion

Exposure time : 2 yr

Cyclosporine:

Species : Rat

NOAEL : 14 mg/kg

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

LOAEL	:	45 mg/kg
Application Route	:	Oral
Exposure time	:	90 Days
Target Organs	:	Kidney, Liver, Immune system
Symptoms	:	hair loss
Species	:	Monkey
NOAEL	:	20 mg/kg
LOAEL	:	60 mg/kg
Application Route	:	Oral
Exposure time	:	90 Days
Target Organs	:	Immune system
Symptoms	:	Gastrointestinal disturbance, Liver disorders, Kidney disorders
Species	:	Dog
LOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Immune system
Symptoms	:	Changes in the blood count, Kidney disorders, Skin disorders, hair loss

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Cyclosporine:**

Inhalation	:	Remarks: May cause irritation of respiratory tract.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Symptoms: Eye irritation, eye pain
Ingestion	:	Symptoms: Kidney disorders, Tremors, hypertension, blood effects, Gastrointestinal disturbance

Section 12: Ecological information**Ecotoxicity****Components:****Petrolatum:**

Toxicity to fish	:	LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Petrolatum:**

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100757 Veterinary Medicines (Limited Pack Size, Finished Dose) Group Standard 2020

Tolerable Exposure Limits (TEL)

Not applicable

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 06.07.2024

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average
NZ OEL / WES-STEL : Workplace Exposure Standard - Short-Term Exposure Limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.05.2024
9.0	06.07.2024	608887-00023	Date of first issue: 08.04.2016

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN